Shane Schaffer, Cingulate CEO
IPO filings are back on the biotech menu as an ADHD drug developer submits its Nasdaq paperwork
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
The summer months have brought the biotech IPO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
